Close
FINDING CURES TOGETHER<sup>SM</sup>

Bladder Cancer: Transforming the Field

Program 

Saturday, May 18

Sunday, May 19

Monday, May 20

Tuesday, May 21


Saturday, May 18

Welcome and Opening Keynote Session
6:30-7:30 p.m.

Welcome Remarks
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

Keynote Address
Title to be announced
Peter A. Jones, Van Andel Research Institute, Grand Rapids, Michigan


Welcome Reception

7:30-9:30 p.m.


Sunday, May 19

Continental Breakfast
7-8 a.m.


Plenary
Session 1: Molecular Pathology – Omics, Subtypes, Biomarkers
Session Chair: Donna E. Hansel, Oregon Health & Science University, Portland, Oregon
8-10 a.m.

Molecular subtypes and liquid biopsies for predicting outcome in bladder cancer
Lars Dyrskjøt, Aarhus University Hospital, Aarhus, Denmark

Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity
David J. McConkey, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland

Molecular alterations in variant morphology
Donna E. Hansel

The shifting landscape of genomics: Impact on clinical decision making
Seth P. Lerner, Baylor College of Medicine, Houston, Texas


Break

10-10:30 a.m.


Plenary
Session 2 and Panel Discussion: Urine Molecular Diagnosis
Session Chair: Ellen C. Zwarthoff, Erasmus Medical Center, Rotterdam, The Netherlands
10:30 a.m.-12:30 p.m.

Diagnosis of bladder cancer using mutation and methylation biomarkers in urine
Ellen C. Zwarthoff

Title to be announced
Yair Lotan, UT Southwestern Medical Center, Dallas, Texas

Incorporating proteomics in bladder cancer molecular diagnosis
Antonia Vlahou, Biomedical Research Foundation Academy of Athens, Athens, Greece

Panel Discussion


Poster Session A / Lunch

12:30-3 p.m.


Plenary Session 3: Drivers of Disease – Stem Cells, Molecular Pathways, Tumor Microenvironment

Session Chair: William Y. Kim, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
3-5 p.m.

Immune microenvironment in the modulation of therapy response
Keith S. Chan, Baylor College of Medicine, Houston, Texas

Title to be announced
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

Title to be announced
William Y. Kim


Monday, May 20

Continental Breakfast
7-8 a.m.


Plenary
Session 4: Basic and Translational Immuno-Oncology
Session Chair: Charles G. Drake, Columbia University Medical Center, New York, New York
8-10 a.m.

Basic immunological mechanisms of PD-1/PD-L1 blockade
Gordon Freeman, Dana-Farber Cancer Institute, Boston, Massachusetts

NK cell activation and inactivation in the tumor microenvironment: Potential for mobilizing NK cells for cancer therapy
David H. Raulet, UC Berkeley, Berkeley, California

Reverse translation of clinical response in bladder cancer immunotherapy
Matthew Albert, Genentech, Inc., South San Francisco, California

Title to be announced
Charles G. Drake


Break

10-10:30 a.m.


Plenary Session 5: Models for Discovery 

Session Chair: Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California
10:30 a.m.-12:30 p.m.

Genetic mouse models and organoids: Synergy for functional genomics of bladder cancer genes
Francisco X. Real, Spanish National Cancer Center (CNIO), Madrid, Spain

Title to be announced
Michael M. Shen, Columbia University College of Physicians & Surgeons, New York, New York

Genetic modeling of bladder cancer in the post-genome era
Xue-Ru Wu, NYU School of Medicine, New York, New York


Free Time (Lunch on Own)

12:30-3 p.m.


Plenary
Session 6: Management of Noninvasive Disease
Session Chair: Peter C. Black, University of British Columbia, Vancouver, BC, Canada
3-5 p.m.

Title to be announced
Noah M. Hahn, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Title to be announced
Colin P.N. Dinney, The University of Texas MD Anderson Center, Houston, Texas

Realizing the potential of targeted therapy in NMIBC
Peter C. Black


Poster Session B / Reception

5-7:30 p.m.


Tuesday, May 21

Continental Breakfast
7-8 a.m.


Plenary Session 7: Neoadjuvant and Bladder-Sparing Approaches to Invasive Disease
Session Chair: Jason A. Efstathiou, Massachusetts General Hospital, Boston, Massachusetts
8-10 a.m.

Predictive biomarkers of response to neoadjuvant therapy
Kent W. Mouw, Dana-Farber Cancer Institute, Boston, Massachusetts

Molecular biomarkers of chemoradiation response in bladder preservation therapy
David T. Miyamoto, Massachusetts General Hospital, Boston, Massachusetts

Targeting hypoxia and personalizing chemoradiation
Catharine West, University of Manchester, Manchester, United Kingdom

Recent clinical advances in trimodality therapy including combining immunotherapy with chemoradiation
Jason A. Efstathiou


Break

10-10:15 a.m.


Plenary Session 8: Management of Metastatic Disease
Session Chair: Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, New York
10:15 a.m.-12:15 p.m.

New agents in metastatic urothelial carcinoma
Andrea B. Apolo, National Cancer Institute, Bethesda, Maryland

Management of metastatic disease: Evolving paradigms and new approaches
Jonathan E. Rosenberg, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Dean F. Bajorin

Title to be announced
Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, Pennsylvania


Closing Remarks / Discussion

12:15 p.m.


Top of page